| pubmed-article:8161252 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8161252 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:8161252 | lifeskim:mentions | umls-concept:C0072523 | lld:lifeskim |
| pubmed-article:8161252 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:8161252 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:8161252 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:8161252 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8161252 | pubmed:dateCreated | 1994-5-17 | lld:pubmed |
| pubmed-article:8161252 | pubmed:abstractText | The pS2 protein was first detected in the oestrogen-dependent breast cancer cell line MCF-7. It may have prognostic value for primary breast cancer, and could be used to predict clinical responsiveness to endocrine therapy. In a retrospective study, the concentrations of pS2 protein were determined in 434 cytosol specimens using an immunoradiometric assay. The median values (4, 6 and 3 ng/mg protein) and the third quartiles (27, 26 and 29 ng/mg) in benign breast tumours (n = 17), and in primary (n = 325) and recurrent (n = 37) breast carcinomas were of the same order of magnitude. In primary breast cancer, high pS2 values (> 26 ng/mg) correlated significantly with a positive oestrogen receptor (ER) status and a high grade of tumour differentiation (P = 0.01). As many as 85% of the pS2 positive tumours were ER positive. A marginally significant correlation (P = 0.06) was also found between pS2 status and the quantitative expression of the ER. However, the pS2 values in ER positive endometrial carcinomas (n = 12) as well as in other benign and malignant genital tumours (n = 43) were more than 30 times lower than those measured in breast tumours. The results reveal a close association between pS2 protein and ER status which appears to be limited to breast cancer. | lld:pubmed |
| pubmed-article:8161252 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8161252 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8161252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8161252 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8161252 | pubmed:issn | 0932-0067 | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:SchaefferH... | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:CrombachGG | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:NeuhausWW | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:ScharlAA | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:MöbusVV | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:GöhringU JUJ | lld:pubmed |
| pubmed-article:8161252 | pubmed:author | pubmed-author:IngenhorstAA | lld:pubmed |
| pubmed-article:8161252 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8161252 | pubmed:volume | 253 | lld:pubmed |
| pubmed-article:8161252 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8161252 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8161252 | pubmed:pagination | 183-92 | lld:pubmed |
| pubmed-article:8161252 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:meshHeading | pubmed-meshheading:8161252-... | lld:pubmed |
| pubmed-article:8161252 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8161252 | pubmed:articleTitle | Expression of pS2 protein in breast cancer. | lld:pubmed |
| pubmed-article:8161252 | pubmed:affiliation | Department of Obstetrics and Gynecology, University of Köln, Germany. | lld:pubmed |
| pubmed-article:8161252 | pubmed:publicationType | Journal Article | lld:pubmed |
